Elicio's cancer vaccine boosts CAR Ts for solid tumors

The MIT group behind cancer start-up Elicio reported that its technology for boosting immune responses to cancer vaccines can also prime CAR T cells to kill solid tumors.

CAR T cell therapies have been approved to treat hematologic cancers, but have shown little success in treating solid tumors...